Evotec Overview

  • Year Founded
  • 1993

Year Founded

  • Status
  • Public

  • Employees
  • 5,086


  • Stock Symbol
  • EVT

Stock Symbol

  • Investments
  • 67

  • Share Price
  • $14.11
  • (As of Friday Closing)

Evotec General Information


Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The EVT Execute segment, about 75% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis or integrated drug discovery collaborations. The EVT Innovate segment, about 25% of sales, develops proprietary drug discovery programs and assets, which can lead to partnerships with clients. As of 2022, the company has almost 5,000 employees and 17 production sites mainly in Europe and the United States.

Contact Information

Formerly Known As
Evotec BioSystems
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Primary Industry
Drug Discovery
Other Industries
Stock Exchange
Corporate Office
  • Manfred Eigen Campus
  • Essener Bogen 7
  • 22419 Hamburg
  • Germany
+49 040 000000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Evotec Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$14.11 $14.35 $13.72 - $27.04 $2.6B 177M 735K -$0.57

Evotec Financials Summary

In Thousands,
TTM 30-Sep-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020
EV 3,429,654 2,547,319 8,453,787 6,320,026
Revenue 875,793 790,075 730,701 571,010
EBITDA (70,953) 368,369 101,480
Net Income (101,347) (184,684) 254,797 7,156
Total Assets 2,386,406 2,420,666 2,530,696 1,798,626
Total Debt 623,185 543,356 580,735 605,101
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Evotec Valuation & Funding

Deal Type Date Amount Valuation/
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Evotec‘s full profile, request access.

Request a free trial

Evotec Comparisons

HQ Location
Total Raised
Post Valuation
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic
Drug Discovery
Hamburg, Germany
5,086 As of 2023
000000000 00000


aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugia
Basel, Switzerland
00000 As of 0000
000000000 0000

000 00

fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in c
0000 000000000
Cambridge, MA
000 As of 0000
000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Evotec Competitors (45)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Novartis Corporation Basel, Switzerland 00000 0000 000000000 0000
VBI Vaccines Corporation Cambridge, MA 000 000.00 000000000 000.00
Genocea Biosciences Formerly VC-backed Cambridge, MA 00 00000 000000000000
Astellas Pharma Corporation Tokyo, Japan 00000 00000000
Immatics Formerly VC-backed Tuebingen, Germany 000 00000 00000000 00000
You’re viewing 5 of 45 competitors. Get the full list »

Evotec Executive Team (34)

Name Title Board Seat Contact Info
Werner Lanthaler MD Chief Executive Officer
Laetitia Rouxel Chief Financial Officer
Craig Johnstone Ph.D Chief Operating Officer
Dirk Ullmann Ph.D Global Head, Drug Discovery Services at Evotec and Managing Director, Evotec (München) GmbH
Cord Dohrmann Ph.D Chief Scientific Officer
You’re viewing 5 of 34 executive team members. Get the full list »

Evotec Board Members (18)

Name Representing Role Since
0000000 000000000 Mubadala Investment Company Supervisory Board Member 000 0000
000000000 00000-00 Self Board Member 000 0000
000000 00000000 00 Carrick Therapeutics Board Member 000 0000
0000 000-000000000 Self Chairperson of the Supervisory Board 000 0000
00000 0000000 00.0 Self Interim Chief Executive Officer & Supervisory Board Member 000 0000
You’re viewing 5 of 18 board members. Get the full list »

Evotec Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Evotec Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Evotec‘s full profile, request access.

Request a free trial

Evotec Investments & Acquisitions (67)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Aeovian Pharmaceuticals 28-Mar-2024 00000 0000 0000 Drug Discovery
Dark Blue Therapeutics 22-Mar-2024 00000 0000 000.00 Drug Discovery 000000 00
Tubulis 14-Mar-2024 00000 0000 00000 Drug Discovery
NephThera 01-Jul-2023 0000000000 00.000 Drug Discovery
Cajal Neuroscience 29-Nov-2022 Early Stage VC 000.00 Drug Discovery
You’re viewing 5 of 67 investments and acquisitions. Get the full list »

Evotec Subsidiaries (8)

Company Name Industry Location Founded
Just - Evotec Biologics Biotechnology Seattle, WA 2014
Rigenerand Other Devices and Supplies Medolla, Italy 0000
Central Glass Germany Specialty Chemicals Halle, Germany 0000
Kuecept Drug Discovery Potters Bar, United Kingdom 0000
Kinaxo Biotechnologies Drug Discovery Planegg, Germany 0000
You’re viewing 5 of 8 subsidiaries. Get the full list »

Evotec ESG

Risk Overview

Risk Rating

Updated March, 20, 2024

18.59 | Low Risk

Risk Scale

A lower score indicates better sustainability












Exposure refers to the extent to which a company is exposed to different material ESG issues



Management is related to actions taken to manage ESG issues


Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.


Covered Companies

00 of 16,173






00 of 909




Laboratory Equipment and Services


00 of 64




To view Evotec’s complete esg history, request access »

Evotec Exits (4)

Company Name Exit Date Exit Type Exit Size Status Buyers
OxVax 21-Apr-2021 0000 00000 00000 Completed
  • 3 buyers
Pancella 02-Apr-2020 000000000 Completed
  • 000000
Lab10x 24-Jun-2019 00000 0000000 Completed
  • 5 buyers
Forge Therapeutics 01-Dec-2017 Early Stage VC 000.00 Completed
  • 9 buyers
To view Evotec’s complete exits history, request access »

Evotec FAQs

  • When was Evotec founded?

    Evotec was founded in 1993.

  • Who is the founder of Evotec?

    Charles Weissmann Ph.D, Freimut Leidenberger, Heinrich Schulte Ph.D, Rudolf Rigler, Karsten Henco Ph.D, and Manfred Eigen are the founders of Evotec.

  • Who is the CEO of Evotec?

    Werner Lanthaler MD is the CEO of Evotec.

  • Where is Evotec headquartered?

    Evotec is headquartered in Hamburg, Germany.

  • What is the size of Evotec?

    Evotec has 5,086 total employees.

  • What industry is Evotec in?

    Evotec’s primary industry is Drug Discovery.

  • Is Evotec a private or public company?

    Evotec is a Public company.

  • What is Evotec’s stock symbol?

    The ticker symbol for Evotec is EVT.

  • What is the current stock price of Evotec?

    As of 19-Apr-2024 the stock price of Evotec is $14.11.

  • What is the current market cap of Evotec?

    The current market capitalization of Evotec is $2.6B.

  • What is Evotec’s current revenue?

    The trailing twelve month revenue for Evotec is $876M.

  • Who are Evotec’s competitors?

    Novartis, VBI Vaccines, Genocea Biosciences, Astellas Pharma, and Immatics are some of the 45 competitors of Evotec.

  • What is Evotec’s annual earnings per share (EPS)?

    Evotec’s EPS for 12 months was -$0.57.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »